Characterization of heparin interactions with Clostridioides difficile toxins and its potential as anti-CDI therapeutics.|https://dx.doi.org/10.1016/j.carbpol.2024.123143
Clostridioides difficile Infections and Antibiotherapy: Results of Four Years of Observation in a Romanian Tertiary Hospital.|https://dx.doi.org/10.3390/microorganisms12122490
Study on the Efficacy and Safety of Tedizolid in Japanese Patients.|https://dx.doi.org/10.3390/antibiotics13121237
Access in all areas? A roundup of developments in market access and health technology assessment: part 6.|https://dx.doi.org/10.57264/cer-2024-0239
Natural History of Clostridioides difficile-related Disease Progression in the Two-Step Testing Era.|https://dx.doi.org/10.1093/cid/ciaf020
Global burden and trends of the Clostridioides difficile infection-associated diseases from 1990 to 2021: an observational trend study.|https://dx.doi.org/10.1080/07853890.2025.2451762
Fecal microbiota changes associated with pathogenic and non-pathogenic diarrheas in foals.|https://dx.doi.org/10.1186/s13104-025-07110-9
Can Gut Microbiota Analysis Reveal Clostridioides difficile Infection? Evidence from an Italian Cohort at Disease Onset.|https://dx.doi.org/10.3390/microorganisms13010016
Evaluation of Inflammatory Markers and Clinical Outcomes in COVID-19 Patients with Concurrent Clostridioides difficile Infection: A Comparative Cohort Analysis.|https://dx.doi.org/10.3390/biomedicines13010111
